136 related articles for article (PubMed ID: 38039515)
1. Preventing broken hearts in women with breast cancer: a concise review on chemotherapy-mediated cardiotoxicity.
Bews HJ; Mackic L; Jassal DS
Can J Physiol Pharmacol; 2023 Dec; ():. PubMed ID: 38039515
[TBL] [Abstract][Full Text] [Related]
2. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
4. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.
Pituskin E; Mackey JR; Koshman S; Jassal D; Pitz M; Haykowsky MJ; Pagano JJ; Chow K; Thompson RB; Vos LJ; Ghosh S; Oudit GY; Ezekowitz JA; Paterson DI
J Clin Oncol; 2017 Mar; 35(8):870-877. PubMed ID: 27893331
[TBL] [Abstract][Full Text] [Related]
5. The Cardioprotective Role of Flaxseed in the Prevention of Doxorubicin- and Trastuzumab-Mediated Cardiotoxicity in C57BL/6 Mice.
Asselin CY; Lam A; Cheung DYC; Eekhoudt CR; Zhu A; Mittal I; Mayba A; Solati Z; Edel A; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Pierce GN; Niraula S; Jassal DS
J Nutr; 2020 Sep; 150(9):2353-2363. PubMed ID: 32510147
[TBL] [Abstract][Full Text] [Related]
6. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
[TBL] [Abstract][Full Text] [Related]
7. Comparing Flaxseed and Perindopril in the Prevention of Doxorubicin and Trastuzumab-Induced Cardiotoxicity in C57Bl/6 Mice.
Eekhoudt CR; Bortoluzzi T; Varghese SS; Cheung DYC; Christie S; Eastman S; Mittal I; Austria JA; Aukema HM; Ravandi A; Thliveris J; Singal PK; Jassal DS
Curr Oncol; 2022 Apr; 29(5):2941-2953. PubMed ID: 35621631
[TBL] [Abstract][Full Text] [Related]
8. Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial.
Leong DP; Cosman T; Alhussein MM; Kumar Tyagi N; Karampatos S; Barron CC; Wright D; Tandon V; Magloire P; Joseph P; Conen D; Devereaux PJ; Ellis PM; Mukherjee SD; Dhesy-Thind S
JACC CardioOncol; 2019 Sep; 1(1):1-10. PubMed ID: 34396157
[TBL] [Abstract][Full Text] [Related]
9. The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity.
Akolkar G; Bhullar N; Bews H; Shaikh B; Premecz S; Bordun KA; Cheung DY; Goyal V; Sharma AK; Garber P; Singal PK; Jassal DS
Cardiovasc Ultrasound; 2015 Apr; 13():18. PubMed ID: 25889218
[TBL] [Abstract][Full Text] [Related]
10. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.
Nowsheen S; Aziz K; Park JY; Lerman A; Villarraga HR; Ruddy KJ; Herrmann J
J Am Heart Assoc; 2018 Aug; 7(15):e008637. PubMed ID: 30371238
[TBL] [Abstract][Full Text] [Related]
13. The Cardioprotective Role of N-Acetyl Cysteine Amide in the Prevention of Doxorubicin and Trastuzumab-Mediated Cardiac Dysfunction.
Goyal V; Bews H; Cheung D; Premecz S; Mandal S; Shaikh B; Best R; Bhindi R; Chaudhary R; Ravandi A; Thliveris J; Singal PK; Niraula S; Jassal DS
Can J Cardiol; 2016 Dec; 32(12):1513-1519. PubMed ID: 27650929
[TBL] [Abstract][Full Text] [Related]
14. Left Ventricular Global Longitudinal Strain in HER-2 + Breast Cancer Patients Treated with Anthracyclines and Trastuzumab Who Develop Cardiotoxicity Is Associated with Subsequent Recovery of Left Ventricular Ejection Fraction.
Fei HW; Ali MT; Tan TC; Cheng KH; Salama L; Hua L; Zeng X; Halpern EF; Taghian A; MacDonald SM; Scherrer-Crosbie M
Echocardiography; 2016 Apr; 33(4):519-26. PubMed ID: 26992012
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
16. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
17. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
18. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
19. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
Honda K; Takeshita K; Murotani K; Mitsuma A; Hayashi H; Tsunoda N; Kikumori T; Murohara T; Ando Y
Breast Cancer; 2017 Mar; 24(2):312-318. PubMed ID: 27234030
[TBL] [Abstract][Full Text] [Related]
20. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
